Patents by Inventor Devyn McKinley Smith

Devyn McKinley Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions, devices, and methods for treating Fabry disease
    Patent number: 12649930
    Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: June 9, 2026
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
  • IMPLANTABLE PARTICLES AND RELATED METHODS
    Publication number: 20250235409
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: October 30, 2024
    Publication date: July 24, 2025
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS
    Publication number: 20250000788
    Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.
    Type: Application
    Filed: January 26, 2022
    Publication date: January 2, 2025
    Inventors: Sofia Brites Boss, Christopher P. Hencken, Hozefa Bandukwala, Robert James Miller, Omid Veiseh, Devyn McKinley Smith
  • Implantable particles and related methods
    Patent number: 12161760
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 10, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY
    Publication number: 20230123802
    Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 20, 2023
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE
    Publication number: 20220267794
    Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 25, 2022
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
  • IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS
    Publication number: 20220000789
    Abstract: Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 6, 2022
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS
    Publication number: 20210145889
    Abstract: Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 20, 2021
    Inventors: Devyn McKinley Smith, David Peritt, Omid Veiseh, Richard Heidebrecht, Robert James Miller
  • IMPLANTABLE PARTICLES AND RELATED METHODS
    Publication number: 20210145759
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 20, 2021
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
    Publication number: 20200263196
    Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 20, 2020
    Inventors: Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Robert James Miller, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton